202 related articles for article (PubMed ID: 19901101)
1. Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected].
DeAngelis LM
J Clin Oncol; 2009 Dec; 27(35):5861-2. PubMed ID: 19901101
[No Abstract] [Full Text] [Related]
2. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
[TBL] [Abstract][Full Text] [Related]
3. Regimen of procarbazine, lomustine, and vincristine versus temozolomide for gliomas.
Wick W; Winkler F
Cancer; 2018 Jul; 124(13):2674-2676. PubMed ID: 29698549
[No Abstract] [Full Text] [Related]
4. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.
van den Bent MJ; Dubbink HJ; Sanson M; van der Lee-Haarloo CR; Hegi M; Jeuken JW; Ibdaih A; Brandes AA; Taphoorn MJ; Frenay M; Lacombe D; Gorlia T; Dinjens WN; Kros JM
J Clin Oncol; 2009 Dec; 27(35):5881-6. PubMed ID: 19901104
[TBL] [Abstract][Full Text] [Related]
5. Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV.
Levin VA
Oncology (Williston Park); 2015 Apr; 29(4):264, 266-8. PubMed ID: 25952490
[No Abstract] [Full Text] [Related]
6. Temozolomide and radiation in low-grade and anaplastic gliomas: temoradiation.
Schiff D
Cancer Invest; 2007 Dec; 25(8):776-84. PubMed ID: 17952745
[TBL] [Abstract][Full Text] [Related]
7. Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for temozolomide.
Rinne ML; Wen PY
Oncology (Williston Park); 2015 Apr; 29(4):265, 275. PubMed ID: 25952491
[No Abstract] [Full Text] [Related]
8. Therapy for recurrent high-grade gliomas: does continuous dose-intense temozolomide have a role?
Wen PY
J Clin Oncol; 2010 Apr; 28(12):1977-9. PubMed ID: 20308652
[No Abstract] [Full Text] [Related]
9. [Clinicopathological diagnosis of gliomas by genotype analysis].
Nakamura M; Shimada K; Nakase H; Konishi N
Brain Nerve; 2009 Jul; 61(7):773-80. PubMed ID: 19618854
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma.
Bell EH; Zhang P; Shaw EG; Buckner JC; Barger GR; Bullard DE; Mehta MP; Gilbert MR; Brown PD; Stelzer KJ; McElroy JP; Fleming JL; Timmers CD; Becker AP; Salavaggione AL; Liu Z; Aldape K; Brachman DG; Gertler SZ; Murtha AD; Schultz CJ; Johnson D; Laack NN; Hunter GK; Crocker IR; Won M; Chakravarti A
J Clin Oncol; 2020 Oct; 38(29):3407-3417. PubMed ID: 32706640
[TBL] [Abstract][Full Text] [Related]
11. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
[TBL] [Abstract][Full Text] [Related]
12. [Chemotherapy for malignant gliomas].
Nagane M
No Shinkei Geka; 2007 May; 35(5):433-50. PubMed ID: 17491340
[No Abstract] [Full Text] [Related]
13. Phase II study of protracted daily temozolomide for low-grade gliomas in adults.
Kesari S; Schiff D; Drappatz J; LaFrankie D; Doherty L; Macklin EA; Muzikansky A; Santagata S; Ligon KL; Norden AD; Ciampa A; Bradshaw J; Levy B; Radakovic G; Ramakrishna N; Black PM; Wen PY
Clin Cancer Res; 2009 Jan; 15(1):330-7. PubMed ID: 19118062
[TBL] [Abstract][Full Text] [Related]
14. [Management of gliomas].
Lévy S; Chapet S; Mazeron JJ
Cancer Radiother; 2014 Oct; 18(5-6):461-7. PubMed ID: 25201633
[TBL] [Abstract][Full Text] [Related]
15. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.
Brandsma D; Stalpers L; Taal W; Sminia P; van den Bent MJ
Lancet Oncol; 2008 May; 9(5):453-61. PubMed ID: 18452856
[TBL] [Abstract][Full Text] [Related]
16. Low-grade glioma: a challenge in therapeutic options: the role of radiotherapy.
Baumert BG; Stupp R; ;
Ann Oncol; 2008 Sep; 19 Suppl 7():vii217-22. PubMed ID: 18790954
[No Abstract] [Full Text] [Related]
17. Prime time for molecular marker diagnostics in neuro-oncology.
Weller M; Stupp R
Curr Opin Neurol; 2012 Dec; 25(6):743-4. PubMed ID: 23041956
[No Abstract] [Full Text] [Related]
18. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
19. Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells.
Shen D; Guo CC; Wang J; Qiu ZK; Sai K; Yang QY; Chen YS; Chen FR; Wang J; Panasci L; Chen ZP
Oncol Rep; 2015 Nov; 34(5):2715-21. PubMed ID: 26329778
[TBL] [Abstract][Full Text] [Related]
20. [Chemotherapy for brain tumors in adult patients].
Weller M
Nervenarzt; 2008 Feb; 79(2):231-41. PubMed ID: 18253773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
